

This document was valid from March 2008 until March 2018. It is now superseded by a <u>new version</u> adopted by the HMPC on 27 March 2018 and published on the EMA website.

> London, 8 May 2008 Doc. Ref. EMEA/HMPC/179281/2007*Corr.* <sup>1</sup>

# COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC)

#### **FINAL**

#### COMMUNITY HERBAL MONOGRAPH ON CALENDULA OFFICINALIS L., FLOS

DISCUSSION IN WORKING PARTY ON COMMUNITY MONOGRAPHS AND COMMUNITY LIST (MLWP)	May 2007 July 2007
ADOPTION BY HMPC FOR RELEASE FOR CONSULTATION	5 July 2007
END OF CONSULTATION (DEADLINE FOR COMMENTS)	15 October 2007
REDISCUSSION IN WORKING PARTY ON COMMUNITY MONOGRAPHS AND COMMUNITY LIST (MLWP)	January 2008 March 2008
ADOPTION BY HMPC	March 2008

#### KEYWORDS

Herbal medicinal products; HMPC; Community herbal monographs; traditional use; *Calendula officinalis* L.; Calendulae flos; calendula flowers

<sup>&</sup>lt;sup>1</sup> Changes introduced in sections 4.2 and 4.3

#### COMMUNITY HERBAL MONOGRAPH ON CALENDULA OFFICINALIS L., FLOS

#### 1. NAME OF THE MEDICINAL PRODUCT

To be specified for the individual finished product.

#### QUALITATIVE AND QUANTITATIVE COMPOSITION $^{2,3}$ 2.

Well-established use	<u>Traditional use</u>
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Calendula officinalis L., flos (calendula flower)
	i) Herbal substance
	Whole or cut, dried, fully opened flowers,
	which have been detached from the
	receptacle, of the cultivated, double-flowered
	varieties.
	ii) Herbal preparations
	A) Liquid extract (1:1), extraction solvent ethanol
	40-50% (v/v)
	B) Liquid extract (1:1.8-2.2), extraction solvent ethanol 40-50% (v/v)
	C) Tincture (1:5), extraction solvent ethanol
	70-90% (v/v)
	D) Liquid extract (1:10), extraction solvent fatty
	vegetable oil e.g. olive oil
	E) Ointment $(1:5 - 1:25)$ , extraction solvent
	hardened vegetable fat, petroleum jelly <sup>4</sup>
	F) Comminuted herbal substance

#### PHARMACEUTICAL FORM

	or semi solid dosage forms for cutaneous and oromucosal use.  The pharmaceutical form should be described by the European Pharmacopoeia full standard term.
Well-established use	Traditional use  Herbal substance or comminuted herbal substance for infusion or other herbal preparations in liquid

© EMEA 2008 2/6

 $<sup>^2</sup>$  The material complies with the Ph. Eur. monograph (ref. 01/2005:1297).  $^3$  The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

<sup>4</sup> Calendula ointment is prepared by gentle digestion of the herbal substance in the melted ointment base for up to 16 hours

and subsequent filtration and congealment during fall in temperature.

#### 4. CLINICAL PARTICULARS

#### 4.1. Therapeutic indications

a) Traditional herbal medicinal product for the symptomatic treatment of minor inflammations of the skin (such as sunburn) and as an aid in healing of minor wounds.
b) Traditional herbal medicinal product for the symptomatic treatment of minor inflammations in the mouth or the throat.
The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

# 4.2. Posology and method of administration

Well-established use	<u>Traditional use</u>
Well-established use	Posology  i) Herbal substance Infusion for cutaneous and oromucosal application: 1-2 g / 150 ml of water. The still warm infusion is used as such to rinse or gargle for the treatment of inflammations in the mouth or the throat or to prepare impregnated dressings.  ii) Herbal preparations A) Liquid extract (DER 1:1) In semi-solid dosage forms: amount equivalent to 2-10% herbal substance B) Liquid extract (DER 1:1.8-2.2) In semi-solid dosage forms: amount equivalent to 2-5% herbal substance C) Tincture (DER 1:5) In impregnated dressings diluted at least 1:3 with freshly boiled water; in semi-solid dosage forms: amount equivalent to 2-10% herbal substance As a gargle or mouth wash in a 2% solution D) Liquid extract (DER 1:10) In semi-solid dosage forms: amount equivalent to 2-8% herbal substance E) Ointment Equivalent to 4-20% herbal substance Indication a) The use is not recommended in children under 6 years of age (see section 4.4 Special warnings and precautions for use).

© EMEA 2008 3/6

Indication b)
The use is not recommended in children under 12 years of age (see section 4.4 Special warnings and precautions for use).

2 to 4 times daily

Duration of use

Impregnated dressings: remove after 30-60 minutes

All herbal preparations:
If the symptoms persist after 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

Method of administration

#### 4.3. Contraindications

Well-established use	<u>Traditional use</u>
	Hypersensitivity to plants of the Asteraceae
	(Compositae) family.

Cutaneous and oromucosal use.

#### 4.4. Special warnings and precautions for use

Well-established use	Traditional use
	Indication a) The use in children under 6 years of age is not recommended because there is no experience available.
	Indication b) The use in children under 12 years of age is not recommended because there is no experience available.
	If signs of skin infection are observed, a doctor or a qualified health care practitioner should be consulted.

#### 4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	<u>Traditional use</u>
	None reported.

© EMEA 2008 4/6

#### 4.6. Pregnancy and lactation

Well-established use	<u>Traditional use</u>
	Safety during pregnancy and lactation has not been established.  In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

### 4.7. Effects on ability to drive and use machines

Well-established use	<u>Traditional use</u>	
	Not relevant.	

#### 4.8. Undesirable effects

frequency is not known.
tions not mentioned above
a qualified health care
a qualified hea consulted.

#### 4.9. Overdose

Well-established use		<u>Traditional use</u>
		No case of overdose has been reported.

### 5. PHARMACOLOGICAL PROPERTIES

#### 5.1. Pharmacodynamic properties

Well-established use	<u>Traditional use</u>
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

### 5.2. Pharmacokinetic properties

Well-established use	<u>Traditional use</u>
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

© EMEA 2008 5/6

# 5.3. Preclinical safety data

Well-established use	<u>Traditional use</u>
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.
	Available tests on genotoxicity (liquid extract with 60% ethanol) and on carcinogenicity (undefined extract) did not give any reason for concern.
	Tests on reproductive toxicity have not been performed.

#### 6. PHARMACEUTICAL PARTICULARS

Well-established use	<u>Traditional use</u>
	Not applicable.

### 7. DATE OF COMPILATION/LAST REVISION

8 May 2008